These findings align with previous research indicating that HER2 overexpression in biliary tract cancer correlates with reduced DFS, OS, and PFS in patients receiving palliative gemcitabine with cisplatin treatment [28]. This evidence concerns the gene ERBB2 and biliary tract neoplasm.